Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

[Mutation analysis of the HBV reverse transcriptase in nucleos(t)ide-treated patients with chronic HBV infection].

Jiao XJ, Peng X, Jiao XM, Wang JS, Sun XW, Zhao PL, Wang SY, Liu JQ, Li T, Yang JX.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2012 Dec;26(6):453-5. Chinese.

PMID:
23627028
2.

Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.

Yang JX, Liu BM, Li XG, Yan CH, Xu J, Sun XW, Wang YH, Jiao XJ, Yan L, Dong JP, Hou CS, Abuduheilili X, Li T, Zhuang H.

Antivir Ther. 2010;15(8):1171-8. doi: 10.3851/IMP1677.

PMID:
21149924
3.

Monitoring of genotypic resistance profile in chronic hepatitis B patients receiving nucleos(t)ide analogues in Huzhou, China.

Qian F, Qin J, Li D, Ma Z, Zhang H, Jin F, Wang W.

J Infect Dev Ctries. 2016 Sep 30;10(9):996-1002. doi: 10.3855/jidc.8020.

5.

Profile of hepatitis B virus resistance mutations against nucleoside/nucleotide analogue treatment in Chinese patients with chronic hepatitis B.

Lei J, Wang Y, Wang LL, Zhang SJ, Chen W, Bai ZG, Xu LY.

Virol J. 2013 Oct 25;10:313. doi: 10.1186/1743-422X-10-313.

6.

Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection.

Liu Y, Wang C, Zhong Y, Li X, Dai J, Ren X, Xu Z, Li L, Yao Z, Ji D, Wang L, Zhang L, Wong VW, Zoulim F, Xu D.

J Viral Hepat. 2011 Apr;18(4):e29-39. doi: 10.1111/j.1365-2893.2010.01360.x. Epub 2010 Sep 6.

PMID:
21392168
7.

Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.

Li X, Liu Y, Zhao P, Wang Y, Chen L, Xin S, Zhang XX, Xu D.

Antivir Ther. 2015;20(2):141-7. doi: 10.3851/IMP2813. Epub 2014 Jul 3.

PMID:
24992206
8.

Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients.

Liu BM, Li T, Xu J, Li XG, Dong JP, Yan P, Yang JX, Yan L, Gao ZY, Li WP, Sun XW, Wang YH, Jiao XJ, Hou CS, Zhuang H.

Antiviral Res. 2010 Mar;85(3):512-9. doi: 10.1016/j.antiviral.2009.12.006. Epub 2009 Dec 23.

PMID:
20034521
9.
10.

Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs.

Salpini R, Svicher V, Cento V, Gori C, Bertoli A, Scopelliti F, Micheli V, Cappiello T, Spanò A, Rizzardini G, De Sanctis GM, Sarrecchia C, Angelico M, Perno CF.

Antiviral Res. 2011 Nov;92(2):382-5. doi: 10.1016/j.antiviral.2011.08.013. Epub 2011 Sep 5.

PMID:
21920388
11.
12.

[Analysis and recombinant construction of HBV the reverse transcriptase gene with drug-resistant mutations from 40 patients with chronic hepatitis B].

Su HL, Liu Y, Liu W, Zhong YW, Chen XY, Wang CM, Liu YM, Xu DP.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2009 Oct;23(5):340-2. Chinese.

PMID:
20387480
13.

Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.

Enomoto M, Tamori A, Kohmoto MT, Morikawa H, Habu D, Sakaguchi H, Takeda T, Seki S, Kawada N, Shiomi S, Nishiguchi S.

J Med Virol. 2007 Nov;79(11):1664-70.

PMID:
17854034
14.

Mutations in Pol gene of hepatitis B virus in patients with chronic hepatitis B before and after therapy with nucleoside/nucleotide analogues.

Januszkiewicz-Lewandowska D, Rucka A, Kowala-Piaskowska A, Bereszynska I, Mozer-Lisewska I, Zajac-Spychala O, Wysocki J, Nowak J.

Acta Virol. 2014;58(2):185-9.

PMID:
24957725
15.

Antiviral drug-associated potential vaccine-escape hepatitis B virus mutants in Turkish patients with chronic hepatitis B.

Sayan M, Akhan SC.

Int J Infect Dis. 2011 Oct;15(10):e722-6. doi: 10.1016/j.ijid.2011.05.019. Epub 2011 Jul 23.

16.

Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy.

Mirandola S, Sebastiani G, Rossi C, Velo E, Erne EM, Vario A, Tempesta D, Romualdi C, Campagnolo D, Alberti A.

Antiviral Res. 2012 Dec;96(3):422-9. doi: 10.1016/j.antiviral.2012.09.014. Epub 2012 Sep 28.

PMID:
23026293
17.

Monitoring of therapy in patients with chronic hepatitis B virus.

Arrese E, Basaras M, Blanco S, Ruiz P, Cisterna R.

Eur J Gastroenterol Hepatol. 2010 Jun;22(6):736-40. doi: 10.1097/MEG.0b013e32832e0a44.

PMID:
19550344
18.
19.

Nucleotide analogue-resistant mutations in hepatitis B viral genomes found in hepatitis B patients.

Fan J, Zhang Y, Xiong H, Wang Y, Guo X.

J Gen Virol. 2015 Mar;96(Pt 3):663-70. doi: 10.1099/jgv.0.000010. Epub 2014 Dec 6.

PMID:
25481755
20.

Role of the line probe assay INNO-LiPA HBV DR and ultradeep pyrosequencing in detecting resistance mutations to nucleoside/nucleotide analogues in viral samples isolated from chronic hepatitis B patients.

Mese S, Arikan M, Cakiris A, Abaci N, Gumus E, Kursun O, Onel D, Ustek D, Kaymakoglu S, Badur S, Yenen OS, Bozkaya E.

J Gen Virol. 2013 Dec;94(Pt 12):2729-38. doi: 10.1099/vir.0.053041-0. Epub 2013 Sep 17.

PMID:
24045109

Supplemental Content

Support Center